Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04313634 · ClinicalTrials.gov registry record · Phase 2
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
A Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT04313634: Completed Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..
NCT04313634 is a Phase 2 study of Healthy that has completed, run by Sundeep Khosla, M.D.. The registered enrollment target is 74 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04313634, a Phase 2 study of Healthy, has completed, sponsored by Sundeep Khosla, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
Primary Outcome
Percent change in serum bone turnover markers C-terminal telopeptide of type I collagen \[CTX\]. The C-terminal telopeptide (CTX), also known as carboxy-terminal collagen crosslinks, is a biomarker used to measure the rate of bone turnover. It provides valuable information for assessing bone health and evaluating treatment responses.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Fisetin
- DRUG Quercetin
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 2 |
What the finished NCT04313634 record still lists
NCT04313634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Dasatinib is the first listed.
NCT04313634 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04313634 about?
NCT04313634 is a clinical study titled "Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans". To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
What is the current status of trial NCT04313634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2020-06-09. Estimated completion is 2023-06-06.
What conditions does trial NCT04313634 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04313634?
The interventions under investigation include: Dasatinib (DRUG), Fisetin (DRUG), Quercetin (DRUG).
Who is sponsoring clinical trial NCT04313634?
This trial is sponsored by Sundeep Khosla, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04313634 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04313634's enrollment target sits among peer trials
74 311th of 1090 higher than 779 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI